Quality control analyst
TBD Pharmatech

About TBD Pharmatech

Pharmaceutical API CDMO

Specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and other fine chemicals, TBD Pharmatech (formerly known as TBD-Biodiscovery) stands as a Contract Development and Manufacturing Organization (CDMO) with an established industry presence since 2006. We leverage our robust R&D capabilities and GMP-compliant manufacturing facilities (since 2008), including a state-of-the-art plant currently in construction in Tartu, Estonia.

Located within the European Union and ISO 9001 certified, our international team is devoted to forging lasting connections with our global customer base. International projects account for ~95% of our portfolio—we are adept at navigating complex regulatory landscapes all over the world.

Our tailored suite of services encompasses every stage of chemical development, making us your ideal partner for transforming innovative concepts into commercially viable products. Our commitment to quality and customer satisfaction is affirmed by enduring client relationships: around 80% of our business is generated from returning customers.

Meet the team


ISO 9001

ISO 9001:2015 is a globally recognized standard for quality management systems (QMS). Developed by the International Organization for Standardization (ISO), it sets the framework for the processes, procedures, and responsibilities required to achieve consistent product quality focusing on client satisfaction, risk management, and continuous improvement.

Organizations that attain this certification have demonstrated their capability to consistently deliver products or services that meet client and regulatory requirements.

Good Manufacturing Practice (GMP)

Good Manufacturing Practices (GMP) are the guidelines and regulations that govern the manufacturing, testing, and quality assurance of pharmaceuticals, including active pharmaceutical ingredients (APIs), finished dosage forms, and medical devices.

GMP compliance ensures that products are consistently produced and controlled according to quality standards and are safe and effective for their intended use. The guidelines encompass everything from raw material sourcing and production facility design to personnel training and record-keeping.


TBD’s current site including R&D labs, GMP compliant manufacturing areas and support staff areas are in Tartu Biotechnology Park, Tartu, Estonia.

Currently, TBD is planning an expansion and is in process of constructing a new complex for development and production that significantly expands the available operational capacities.


  • 2023

    Start of construction for an expanded manufacturing facility in Tartu, Estonia.

  • 2022

    Our team has grown to 60 skilled professionals, each possessing crucial competencies essential for our operations. We’ve extensively digitized our process management to enhance communication efficiency. To represent our range of services and expertise more accurately, we’ve rebranded from TBD-Biodiscovery to TBD Pharmatech.

  • 2020

    Despite the challenges presented in 2020, the year marked some notable achievements for our organization. We were honoured with multiple accolades from both local and national institutions, including recognition as the Best Fast-Growing Small and Medium-Sized Enterprise in Estonia, the top company in the field of Life Sciences, and a ranking as the leading firm among Estonia’s Top 10 Chemistry Companies. In addition, we acquired two hectares of land near Tartu and initiated the design phase for our new development and production facilities.

  • 2019

    A substantial 95% of our product and service portfolio was directed to international markets, primarily serving markets in Germany, the Netherlands, Latvia, Israel, and South Korea. This significant milestone was further amplified by a strategic acquisition; SEAL Investments B.V., a Dutch investment entity, acquired a 30% stake in our company.

  • 2018

    TBD’s workforce had expanded to 42 highly qualified employees, a third of whom hold doctoral degrees. In a commitment to deliver unparalleled service quality, the company achieved ISO 9001 certification. Existing manufacturing capabilities were up-scaled.

  • 2013

    TBD had significantly expanded its global footprint, forging partnerships with countries beyond the EU, including Israel, Russia, Switzerland, and the United States. The company also established collaborations with local academic institutions, offering trainee positions and sponsoring chemistry competitions like the Estonian and Baltics Chemistry Olympiads. That year, TBD enhanced its capabilities by adding a GMP-compliant cytotoxic room and securing EU and U.S. patents for amrubicin semisynthetic technology.

  • 2012

    TBD transitioned into a specialized Contract Development and Manufacturing Organization (CDMO), with a focus on synthetic chemistry, downstream processing, and the production of commercial APIs and Investigational Medicinal Products (IMPs) for clinical trials. The company’s chemistry acumen received international acclaim when it secured victory in the HealthPort Innovation Competition.

  • 2010

    At this stage, our team had expanded to 13 professionals, eight of whom held PhDs. Specializing in solving complex synthesis challenges, TBD undertook projects that were previously considered unfeasible by other organizations. Additionally, we initiated the development of bioluminescent compounds.

  • 2008

    TBD received EU GMP certification for non-sterile production, enabling us to provide scale-up services to our clients. With advanced technical capabilities, we could produce compounds in quantities ranging from milligrams to kilograms.

  • 2007

    We expanded our operations with new laboratories in Tartu’s Biotechnology Park, continuing to offer services such as route development and small-scale synthesis. Additionally, we initiated collaborations with neighbouring countries, including Finland, Sweden, and Latvia.

  • 2006

    TBD-Biodiscovery originated as a spinoff company from the University of Tartu.

Galmed Pharmaceuticals
Double Bound Pharmaceutical
Alfasan International